Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Efficacy of Adoptive Therapy with Tumor-infiltrating Lymphocytes and Recombinant Interleukin-2 in Advanced Cutaneous Melanoma: A Systematic Review and Meta-analysis.

Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G.

Ann Oncol. 2019 Sep 30. pii: mdz398. doi: 10.1093/annonc/mdz398. [Epub ahead of print]

PMID:
31566658
2.

ILC regulation of T cell responses in inflammatory diseases and cancer.

Warner K, Ohashi PS.

Semin Immunol. 2019 Feb;41:101284. doi: 10.1016/j.smim.2019.101284. Epub 2019 Aug 2. Review.

PMID:
31383506
3.
4.

Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials.

Gadalla R, Noamani B, MacLeod BL, Dickson RJ, Guo M, Xu W, Lukhele S, Elsaesser HJ, Razak ARA, Hirano N, McGaha TL, Wang B, Butler M, Guidos CJ, Ohashi PS, Siu LL, Brooks DG.

Front Oncol. 2019 May 17;9:415. doi: 10.3389/fonc.2019.00415. eCollection 2019.

5.

Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer.

Jiang DM, Fyles A, Nguyen LT, Neel BG, Sacher A, Rottapel R, Wang BX, Ohashi PS, Sridhar SS.

Oncotarget. 2019 Apr 26;10(31):2947-2958. doi: 10.18632/oncotarget.26893. eCollection 2019 Apr 26.

6.

Turning the Tide Against Regulatory T Cells.

Han S, Toker A, Liu ZQ, Ohashi PS.

Front Oncol. 2019 Apr 16;9:279. doi: 10.3389/fonc.2019.00279. eCollection 2019. Review.

7.

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL.

J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0.

8.

Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.

Nguyen LT, Saibil SD, Sotov V, Le MX, Khoja L, Ghazarian D, Bonilla L, Majeed H, Hogg D, Joshua AM, Crump M, Franke N, Spreafico A, Hansen A, Al-Habeeb A, Leong W, Easson A, Reedijk M, Goldstein DP, McCready D, Yasufuku K, Waddell T, Cypel M, Pierre A, Zhang B, Boross-Harmer S, Cipollone J, Nelles M, Scheid E, Fyrsta M, Lo CS, Nie J, Yam JY, Yen PH, Gray D, Motta V, Elford AR, DeLuca S, Wang L, Effendi S, Ellenchery R, Hirano N, Ohashi PS, Butler MO.

Cancer Immunol Immunother. 2019 May;68(5):773-785. doi: 10.1007/s00262-019-02307-x. Epub 2019 Feb 11.

PMID:
30747243
9.

Choline acetyltransferase-expressing T cells are required to control chronic viral infection.

Cox MA, Duncan GS, Lin GHY, Steinberg BE, Yu LX, Brenner D, Buckler LN, Elia AJ, Wakeham AC, Nieman B, Dominguez-Brauer C, Elford AR, Gill KT, Kubli SP, Haight J, Berger T, Ohashi PS, Tracey KJ, Olofsson PS, Mak TW.

Science. 2019 Feb 8;363(6427):639-644. doi: 10.1126/science.aau9072.

PMID:
30733420
10.

In vitro-generated MART-1-specific CD8 T cells display a broader T-cell receptor repertoire than ex vivo naïve and tumor-infiltrating lymphocytes.

Benveniste PM, Nakatsugawa M, Nguyen L, Ohashi PS, Hirano N, Zúñiga-Pflücker JC.

Immunol Cell Biol. 2019 Apr;97(4):427-434. doi: 10.1111/imcb.12231. Epub 2019 Feb 15.

PMID:
30633397
11.

Activation of Peroxisome Proliferator-Activated Receptors α and δ Synergizes with Inflammatory Signals to Enhance Adoptive Cell Therapy.

Saibil SD, St Paul M, Laister RC, Garcia-Batres CR, Israni-Winger K, Elford AR, Grimshaw N, Robert-Tissot C, Roy DG, Jones RG, Nguyen LT, Ohashi PS.

Cancer Res. 2019 Feb 1;79(3):445-451. doi: 10.1158/0008-5472.CAN-17-3053. Epub 2018 Dec 20.

PMID:
30573521
12.

Generation and molecular recognition of melanoma-associated antigen-specific human γδ T cells.

Benveniste PM, Roy S, Nakatsugawa M, Chen ELY, Nguyen L, Millar DG, Ohashi PS, Hirano N, Adams EJ, Zúñiga-Pflücker JC.

Sci Immunol. 2018 Dec 14;3(30). pii: eaav4036. doi: 10.1126/sciimmunol.aav4036.

PMID:
30552102
13.

CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling.

Mulder DT, Mahé ER, Dowar M, Hanna Y, Li T, Nguyen LT, Butler MO, Hirano N, Delabie J, Ohashi PS, Pugh TJ.

Blood Adv. 2018 Dec 11;2(23):3506-3514. doi: 10.1182/bloodadvances.2017014639. Erratum in: Blood Adv. 2019 Jan 22;3(2):121.

14.

Immunoregulatory functions of innate lymphoid cells.

Crome SQ, Ohashi PS.

J Immunother Cancer. 2018 Nov 19;6(1):121. doi: 10.1186/s40425-018-0433-8.

15.

Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.

Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, Shaw PA, Pugh TJ, Oza AM.

Genome Med. 2018 Oct 31;10(1):81. doi: 10.1186/s13073-018-0590-x.

16.

Timed Regulation of 3BP2 Induction Is Critical for Sustaining CD8+ T Cell Expansion and Differentiation.

Dimitriou ID, Lee K, Akpan I, Lind EF, Barr VA, Ohashi PS, Samelson LE, Rottapel R.

Cell Rep. 2018 Jul 31;24(5):1123-1135. doi: 10.1016/j.celrep.2018.06.075.

17.

Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma.

Toker A, Nguyen LT, Stone SC, Yang SYC, Katz SR, Shaw PA, Clarke BA, Ghazarian D, Al-Habeeb A, Easson A, Leong WL, McCready DR, Reedijk M, Guidos CJ, Pugh TJ, Bernardini MQ, Ohashi PS.

Clin Cancer Res. 2018 Nov 15;24(22):5685-5696. doi: 10.1158/1078-0432.CCR-18-0554. Epub 2018 Jul 31.

PMID:
30065096
18.

Radiation and Heat Improve the Delivery and Efficacy of Nanotherapeutics by Modulating Intratumoral Fluid Dynamics.

Stapleton S, Dunne M, Milosevic M, Tran CW, Gold MJ, Vedadi A, Mckee TD, Ohashi PS, Allen C, Jaffray DA.

ACS Nano. 2018 Aug 28;12(8):7583-7600. doi: 10.1021/acsnano.7b06301. Epub 2018 Jul 20.

PMID:
30004666
19.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J.

Lancet. 2018 May 26;391(10135):2128-2139. doi: 10.1016/S0140-6736(18)30789-X. Epub 2018 May 10.

PMID:
29754777
20.

Rational design and identification of immuno-oncology drug combinations.

Iafolla MAJ, Selby H, Warner K, Ohashi PS, Haibe-Kains B, Siu LL.

Eur J Cancer. 2018 May;95:38-51. doi: 10.1016/j.ejca.2018.02.027. Epub 2018 Apr 7. Review.

PMID:
29631102
21.

Pillars Article: Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function. Science. 1997. 275: 540-543.

Mittrücker HW, Matsuyama T, Grossman A, Kündig TM, Potter J, Shahinian A, Wakeham A, Patterson B, Ohashi PS, Mak TW.

J Immunol. 2017 Dec 1;199(11):3717-3720. No abstract available.

22.

Glycogen Synthase Kinase-3 Modulates Cbl-b and Constrains T Cell Activation.

Tran CW, Saibil SD, Le Bihan T, Hamilton SR, Lang KS, You H, Lin AE, Garza KM, Elford AR, Tai K, Parsons ME, Wigmore K, Vainberg MG, Penninger JM, Woodgett JR, Mak TW, Ohashi PS.

J Immunol. 2017 Dec 15;199(12):4056-4065. doi: 10.4049/jimmunol.1600396. Epub 2017 Nov 6.

23.

Notch Shapes the Innate Immunophenotype in Breast Cancer.

Shen Q, Cohen B, Zheng W, Rahbar R, Martin B, Murakami K, Lamorte S, Thompson P, Berman H, Zúñiga-Pflücker JC, Ohashi PS, Reedijk M.

Cancer Discov. 2017 Nov;7(11):1320-1335. doi: 10.1158/2159-8290.CD-17-0037. Epub 2017 Aug 8.

24.

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.

Lheureux S, Denoyelle C, Ohashi PS, De Bono JS, Mottaghy FM.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):41-54. doi: 10.1007/s00259-017-3695-3. Epub 2017 Apr 10. Review.

25.

Costimulation, a surprising connection for immunotherapy.

Clouthier DL, Ohashi PS.

Science. 2017 Mar 31;355(6332):1373-1374. doi: 10.1126/science.aan1467. No abstract available.

PMID:
28360282
26.

Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target.

MacGregor HL, Ohashi PS.

Clin Cancer Res. 2017 Jun 15;23(12):2934-2941. doi: 10.1158/1078-0432.CCR-15-2440. Epub 2017 Mar 21. Review.

27.

Exposure to sequestered self-antigens in vivo is not sufficient for the induction of autoimmune diabetes.

Ono N, Murakami K, Chan O, Hall H, Elford AR, Yen P, Calzascia T, Spencer DM, Ohashi PS, Dhanji S.

PLoS One. 2017 Mar 3;12(3):e0173176. doi: 10.1371/journal.pone.0173176. eCollection 2017.

28.

A distinct innate lymphoid cell population regulates tumor-associated T cells.

Crome SQ, Nguyen LT, Lopez-Verges S, Yang SY, Martin B, Yam JY, Johnson DJ, Nie J, Pniak M, Yen PH, Milea A, Sowamber R, Katz SR, Bernardini MQ, Clarke BA, Shaw PA, Lang PA, Berman HK, Pugh TJ, Lanier LL, Ohashi PS.

Nat Med. 2017 Mar;23(3):368-375. doi: 10.1038/nm.4278. Epub 2017 Feb 6.

29.

K48-linked KLF4 ubiquitination by E3 ligase Mule controls T-cell proliferation and cell cycle progression.

Hao Z, Sheng Y, Duncan GS, Li WY, Dominguez C, Sylvester J, Su YW, Lin GH, Snow BE, Brenner D, You-Ten A, Haight J, Inoue S, Wakeham A, Elford A, Hamilton S, Liang Y, Zúñiga-Pflücker JC, He HH, Ohashi PS, Mak TW.

Nat Commun. 2017 Jan 13;8:14003. doi: 10.1038/ncomms14003.

30.

An interaction between Scribble and the NADPH oxidase complex controls M1 macrophage polarization and function.

Zheng W, Umitsu M, Jagan I, Tran CW, Ishiyama N, BeGora M, Araki K, Ohashi PS, Ikura M, Muthuswamy SK.

Nat Cell Biol. 2016 Nov;18(11):1244-1252. doi: 10.1038/ncb3413. Epub 2016 Oct 3.

PMID:
27694890
31.

RAIDD Mediates TLR3 and IRF7 Driven Type I Interferon Production.

Maney SK, Xu HC, Huang J, Pandyra AA, Ehlting C, Aguilar-Valenzuela R, Pozdeev VI, McIlwain DR, Zimmermann A, Bode JG, Hengel H, Kirschning CJ, Kim IR, Hiscott J, Brenner D, Häussinger D, Ohashi PS, Mak TW, Lang KS, Lang PA.

Cell Physiol Biochem. 2016;39(4):1271-80. doi: 10.1159/000447832. Epub 2016 Sep 8.

32.

Zeroing in on Tumor-Reactive TILs.

Ohashi PS.

Cancer Immunol Res. 2016 Sep 2;4(9):719. doi: 10.1158/2326-6066.CIR-16-0179.

33.

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule.

Kaufman HL, Butterfield LH, Coulie PG, Demaria S, Ferris RL, Galon J, Khleif SN, Mellman I, Ohashi PS, Overwijk WW, Topalian SL, Marincola FM.

J Immunother Cancer. 2016 Jun 21;4:37. doi: 10.1186/s40425-016-0142-0. eCollection 2016.

34.

B7-H4 is a positive regulator of antitumor immunity.

Rahbar R, Ohashi PS.

Oncoimmunology. 2015 Jun 1;5(1):e1050575. eCollection 2016.

35.

Central tolerance: what you see is what you don't get!

Millar DG, Ohashi PS.

Nat Immunol. 2016 Feb;17(2):115-6. doi: 10.1038/ni.3373. No abstract available.

PMID:
26784256
36.

A Lymphotoxin/Type I IFN Axis Programs CD8+ T Cells To Infiltrate a Self-Tissue and Propagate Immunopathology.

Ng D, Maître B, Cummings D, Lin A, Ward LA, Rahbar R, Mossman KL, Ohashi PS, Gommerman JL.

J Immunol. 2015 Nov 15;195(10):4650-9. doi: 10.4049/jimmunol.1501053. Epub 2015 Oct 12.

37.

miR-155 Upregulation in Dendritic Cells Is Sufficient To Break Tolerance In Vivo by Negatively Regulating SHIP1.

Lind EF, Millar DG, Dissanayake D, Savage JC, Grimshaw NK, Kerr WG, Ohashi PS.

J Immunol. 2015 Nov 15;195(10):4632-40. doi: 10.4049/jimmunol.1302941. Epub 2015 Oct 7.

38.

Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP(+)/NADPH ratio.

Itsumi M, Inoue S, Elia AJ, Murakami K, Sasaki M, Lind EF, Brenner D, Harris IS, Chio II, Afzal S, Cairns RA, Cescon DW, Elford AR, Ye J, Lang PA, Li WY, Wakeham A, Duncan GS, Haight J, You-Ten A, Snow B, Yamamoto K, Ohashi PS, Mak TW.

Cell Death Differ. 2015 Nov;22(11):1837-45. doi: 10.1038/cdd.2015.38. Epub 2015 Apr 17.

39.

Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation.

Bornancin F, Renner F, Touil R, Sic H, Kolb Y, Touil-Allaoui I, Rush JS, Smith PA, Bigaud M, Junker-Walker U, Burkhart C, Dawson J, Niwa S, Katopodis A, Nuesslein-Hildesheim B, Weckbecker G, Zenke G, Kinzel B, Traggiai E, Brenner D, Brüstle A, St Paul M, Zamurovic N, McCoy KD, Rolink A, Régnier CH, Mak TW, Ohashi PS, Patel DD, Calzascia T.

J Immunol. 2015 Apr 15;194(8):3723-34. doi: 10.4049/jimmunol.1402254. Epub 2015 Mar 11.

40.

Deficiency of the B cell-activating factor receptor results in limited CD169+ macrophage function during viral infection.

Xu HC, Huang J, Khairnar V, Duhan V, Pandyra AA, Grusdat M, Shinde P, McIlwain DR, Maney SK, Gommerman J, Löhning M, Ohashi PS, Mak TW, Pieper K, Sic H, Speletas M, Eibel H, Ware CF, Tumanov AV, Kruglov AA, Nedospasov SA, Häussinger D, Recher M, Lang KS, Lang PA.

J Virol. 2015 May;89(9):4748-59. doi: 10.1128/JVI.02976-14. Epub 2015 Feb 11.

41.

Clinical blockade of PD1 and LAG3--potential mechanisms of action.

Nguyen LT, Ohashi PS.

Nat Rev Immunol. 2015 Jan;15(1):45-56. doi: 10.1038/nri3790. Review.

PMID:
25534622
42.

B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.

Rahbar R, Lin A, Ghazarian M, Yau HL, Paramathas S, Lang PA, Schildknecht A, Elford AR, Garcia-Batres C, Martin B, Berman HK, Leong WL, McCready DR, Reedijk M, Done SJ, Miller N, Youngson B, Suh WK, Mak TW, Ohashi PS.

Cancer Immunol Res. 2015 Feb;3(2):184-95. doi: 10.1158/2326-6066.CIR-14-0113. Epub 2014 Dec 19.

43.

Toso regulates differentiation and activation of inflammatory dendritic cells during persistence-prone virus infection.

Lang PA, Meryk A, Pandyra AA, Brenner D, Brüstle A, Xu HC, Merches K, Lang F, Khairnar V, Sharma P, Funkner P, Recher M, Shaabani N, Duncan GS, Duhan V, Homey B, Ohashi PS, Häussinger D, Knolle PA, Honke N, Mak TW, Lang KS.

Cell Death Differ. 2015 Jan;22(1):164-73. doi: 10.1038/cdd.2014.138. Epub 2014 Sep 26.

44.

Chronic viral infection promotes sustained Th1-derived immunoregulatory IL-10 via BLIMP-1.

Parish IA, Marshall HD, Staron MM, Lang PA, Brüstle A, Chen JH, Cui W, Tsui YC, Perry C, Laidlaw BJ, Ohashi PS, Weaver CT, Kaech SM.

J Clin Invest. 2014 Aug;124(8):3455-68. doi: 10.1172/JCI66108. Epub 2014 Jul 8.

45.

Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity.

Xu HC, Grusdat M, Pandyra AA, Polz R, Huang J, Sharma P, Deenen R, Köhrer K, Rahbar R, Diefenbach A, Gibbert K, Löhning M, Höcker L, Waibler Z, Häussinger D, Mak TW, Ohashi PS, Lang KS, Lang PA.

Immunity. 2014 Jun 19;40(6):949-60. doi: 10.1016/j.immuni.2014.05.004. Epub 2014 Jun 5.

46.

Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant.

Dissanayake D, Murakami K, Tran MD, Elford AR, Millar DG, Ohashi PS.

PLoS One. 2014 Mar 19;9(3):e92380. doi: 10.1371/journal.pone.0092380. eCollection 2014.

47.

Mir-155, a central modulator of T-cell responses.

Lind EF, Ohashi PS.

Eur J Immunol. 2014 Jan;44(1):11-5. Review.

PMID:
24571026
48.

IRF4 and BATF are critical for CD8⁺ T-cell function following infection with LCMV.

Grusdat M, McIlwain DR, Xu HC, Pozdeev VI, Knievel J, Crome SQ, Robert-Tissot C, Dress RJ, Pandyra AA, Speiser DE, Lang E, Maney SK, Elford AR, Hamilton SR, Scheu S, Pfeffer K, Bode J, Mittrücker HW, Lohoff M, Huber M, Häussinger D, Ohashi PS, Mak TW, Lang KS, Lang PA.

Cell Death Differ. 2014 Jul;21(7):1050-60. doi: 10.1038/cdd.2014.19. Epub 2014 Feb 14.

49.

Toso controls encephalitogenic immune responses by dendritic cells and regulatory T cells.

Brenner D, Brüstle A, Lin GH, Lang PA, Duncan GS, Knobbe-Thomsen CB, St Paul M, Reardon C, Tusche MW, Snow B, Hamilton SR, Pfefferle A, Gilani SO, Ohashi PS, Lang KS, Mak TW.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1060-5. doi: 10.1073/pnas.1323166111. Epub 2014 Jan 7.

50.

Mobilizing and evaluating anticancer T cells: pitfalls and solutions.

Robert-Tissot C, Nguyen LT, Ohashi PS, Speiser DE.

Expert Rev Vaccines. 2013 Nov;12(11):1325-40. doi: 10.1586/14760584.2013.843456. Epub 2013 Oct 16. Review.

PMID:
24127850

Supplemental Content

Loading ...
Support Center